Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Patients with HER2-low breast cancer have limited targeted treatment options for progressing disease after primary therapy. An antibody–drug conjugate has shown efficacy in early trials.

New research findings are summarized in a short video.